Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Curcumin
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SignPath Pharma to Focus on Coronavirus Disease (COVID-19)
Details : Lipocurc has advantage of not only safely suppressing interleukin-6 by 83%, it also profoundly suppresses TNF-alpha by 77% and IL-1 beta by 85% as well as suppressing RANTES, IL-8, MCP-1& MIP-alpha.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 17, 2020
Lead Product(s) : Curcumin
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase I
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable